AMAG Pharmaceuticals — JP Morgan 38th Healthcare Conference 2020
33 slides from AMAG Pharmaceuticals's conference presentation, Jan 9, 2020

Slide 1: AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020
AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020 © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 1

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, 2019

Slide 3: 2019 In Review
2019 In Review 3

Slide 4: AMAG's 2019 Year In Review
AMAG's 2019 Year In Review Option 4 Completed acquisition of Perosphere Pharmaceuticals and added ciraparantag to development portfolio Grew Feraheme to record revenue of $167M-$169M and achieved Q4 market share of 17.7%1 • IM supply disruptions resulted in removal of both brand and authorized gener

Slide 5: 2019 Financial Results
2019 Financial Results Preliminary and unaudited ($M) Actual Preliminary Preliminary Guidance 9-months 2019 Q4-2019 FY 2019 FY 2019 Revenue Feraheme $126 $40 - $42 $167- 169 -- Makena 97 24 - 27 120 - 123 -- Intrarosa 15 6.5 21 -- Other product revenue -- (0.5) (1) -- Collaboration revenue1 -- 16 16

Slide 6: Recently Announced News – January 9, 2020
Recently Announced News – January 9, 2020 6

Slide 7: Experienced Leadership Team Committed to Realize AMAG's Potential
Experienced Leadership Team Committed to Realize AMAG’s Potential Leadership Transition William Heiden will step down as • AMAG’s Board of Directors has initiated a search for his successor, which it expects to complete by mid-2020 President and Chief Executive Officer • Mr. Heiden will remain in hi

Slide 8: Current Portfolio Valuable but Requires Extensive Resources
Current Portfolio Valuable but Requires Extensive Resources PHYSICIAN/CONSUMER(DTC) PHYSICIAN DRIVEN DRIVEN Hematology Maternal Health Women’s Health COMMERCIAL Divest PIPELINE Ciraparantag AMAG-423 Divest Vyleesi and Intrarosa Completed strategic review of product portfolio • Vyleesi launch is off

Slide 9: Streamlined Portfolio and Infrastructure Positions AMAG for Profitability
Streamlined Portfolio and Infrastructure Positions AMAG for Near- and Long-term Profitability PHYSICIAN DRIVEN PORTFOLIO Hematology Maternal Health SNAPSHOT 2020 COMMERCIAL PIPELINE Ciraparantag AMAG-423 Feraheme • Provides continued growth and positive cash flow ‒ Sufficient to fund pipeline assets

Slide 10: 2020 Financial Guidance Reflects a Return to Positive Adjusted EBITDA
2020 Financial Guidance Reflects a Return to Positive Adjusted EBITDA 2020 FINANCIAL GUIDANCE1 ($M) Total revenue $230 - $280 Operating income2 $2 - $32 Adjusted EBITDA3 $20 - $50 Continued growth of Risk-adjusted topline view of Significant reduction in Feraheme to fund the Makena given the uncerta

Slide 11: Core Value Drivers: 2020 and Beyond
Core Value Drivers: 2020 and Beyond 11

Slide 12: Feraheme (ferumoxytol injection)
Feraheme® (ferumoxytol injection) 12

Slide 13: Continued Strong Feraheme Performance
Continued Strong Feraheme Performance1 $200 Consistent Revenue Growth $100 Revenue ($M) $0 2017 2018 2019 • Build on strong performance of past years, including record annual 2019 revenues 300,000 − Performance-based contracting drives volume, Consistent with stable price Volume 200,000 Growth 100,0

Slide 14: Makena (hydroxyprogesterone caproate injection)
Makena® (hydroxyprogesterone caproate injection) 14

Slide 15: Preterm Birth is a Significant Public Health Issue in the U.S.
Preterm Birth is a Significant Public Health Issue in the U.S. MEIS TRIAL PROLONG TRIAL Conducted in U.S. patient population Conducted primarily in non-U.S. which had a high rate of preterm birth patient population Demonstrated a Did not show a reduction in preterm birth rates 30% reduction Lower ri

Slide 16: Managing Makena to Remain Cash Flow Positive in 2020
Managing Makena to Remain Cash Flow Positive in 2020 Subcutaneous Auto-injector • Well established in the marketplace ‒ Entered 2020 with a strong market share for subcutaneous auto-injector of 63% • Uncertainty surrounding Makena’s future following AdCom meeting ‒ AdCom meeting outcome negatively i

Slide 17: Development Pipeline Ciraparantag
Development Pipeline Ciraparantag 17

Slide 18: Novel Oral Anticoagulant (NOAC) Use Growing
Novel Oral Anticoagulant (NOAC) Use Growing Improved reversal agents could lead to even broader NOAC use Anticoagulants (often referred to as blood thinners) reduce the ability of the blood to form clots • Prevention of stroke in patients with nonvalvular atrial fibrillation • Prevention and treatme

Slide 19: Anticoagulants and Need for Reversal Agents
Anticoagulants and Need for Reversal Agents Ciraparantag: in development as an anticoagulant reversal agent • Use of NOACs and LMWH increase risk of serious bleeding complications (1.5%-2% of patients per year)1 • To manage bleeding, a reversal agent may be critical in cases such as: Emergency/urgen

Slide 20: Large Unmet Medical Need with Significant Global Commercial Potential
Large Unmet Medical Need with Significant Global Commercial Potential Large unmet medical need • Opportunity to provide an improved reversal agent to NOACs Numerous characteristics suggest U.S. market opportunity ciraparantag may offer a more optimal reversal agent 2 • Ready to use ~6 Million ~150,0

Slide 21: Phase 2b Study of Ciraparantag: Reversal of Xarelto
Phase 2b Study of Ciraparantag: Reversal of Xarelto® Rapid and sustained reversal of NOACs in healthy volunteer study Mean Whole Blood Clotting Time (WBCT) by Timepoint Individual Responder Analysis (n=12 per dose) Ciraparantag or placebo dose 1 100.0% 40% Placebo 100% Baseline +3 days of Ciraparant

Slide 22: Whole Blood Clotting Time (WBCT) is a Good Measure of Anticoagulation
Whole Blood Clotting Time (WBCT) is a Good Measure of Anticoagulation • WBCT is a measure of the time it takes for blood to clot – clinically relevant physiologic outcome Perosphere Technologies’ broad spectrum 1 – WBCT is currently evaluated manually Point-of-Care coagulometer – Anticoagulant activ

Slide 23: AMAG-423
AMAG-423 23

Slide 24: Severe Preeclampsia: Significant Unmet Medical Need Globally
Severe Preeclampsia: Significant Unmet Medical Need Globally AMAG-423 (Digoxin Immune Fab: DIF) in development for the treatment of severe preeclampsia Preeclampsia is the Maternal morbidity Adverse neonatal leading cause of: and mortality outcomes No effective treatments FDA granted AMAG-423 Signif

Slide 25: Large Unmet Medical Need with Significant Global Commercial Potential
Large Unmet Medical Need with Significant Global Commercial Potential Annual U.S. incidence of Annual U.S. incidence of preeclampsia SEVERE preeclampsia Large unmet medical need ~140,000 ~50,000 pregnant women1 pregnant women2 Potential ex-U.S. opportunities Every 1% of patients with severe preeclam

Slide 26: Strong Scientific Rationale for AMAG-423
Strong Scientific Rationale for AMAG-423 Reverses effect of EDLFs on sodium pump activity MECHANISM OF ACTION • Endogenous digitalis-like factors (EDLFs) are 30 DEEP Trial4: Sodium Pump Activity circulating inhibitors of the Na+ K+ ATPase pump 25 (Surrogate for EDLF Activity) (“sodium pump”) and whe

Slide 27: DEEP Trial: Improvements in Select Neonatal Outcome Measures
DEEP Trial: Improvements in Select Neonatal Outcome Measures1 Primary composite endpoint in current Phase 2b/3a study of AMAG-423 Intraventricular Hemorrhage (IVH) Necrotizing Enterocolitis (NEC) Deaths Severe (grades 3 and 4) p=0.24 p=0.61 p=0.49 n=3 n=3 n=2 n=1 % of neonatal Deaths neonatal of % %

Slide 28: 2020: Goals and Key Areas of Focus for AMAG
2020: Goals and Key Areas of Focus for AMAG Divest Intrarosa and Work with the FDA Complete successful Drive continued Vyleesi to align with to maintain patient CEO transition Feraheme growth new strategic direction access to Makena Advance ciraparantag Pursue ex-U.S. Meet/exceed and AMAG-423 portfo

Slide 29: Breakout Session: Kent Room
Breakout Session: Kent Room © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 29

Slide 30: Appendix
Appendix 30

Slide 31: Reconciliation of GAAP to Non-GAAP Preliminary Financial Results
Reconciliation of GAAP to Non-GAAP Preliminary Financial Results ($M) 9-Mos 2019 Q4-2019 FY 2019 GAAP operating loss ($251.6) ($22) - ($12) ($274) - ($264) Depreciation and intangible asset amortization 13.9 7.0 21.0 Stock-based compensation 13.7 5.0 18.5 Restructuring 7.4 -- 7.4 Transaction/acquisi

Slide 32: Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance
Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance ($M) 2020 Financial Guidance GAAP operating income $2 - $32 Depreciation 2 Stock-based compensation 16 Non-GAAP adjusted EBITDA $20 - $50 APPENDIX © 2020 AMAG Pharmaceuticals, Inc. All rights reserved 32

Slide 33: AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020
AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020 © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 33
Source: SEC EDGAR · 8-K filed Jan 9, 2020
More decks from AMAG Pharmaceuticals Inc
Q2 2020 Earnings Presentation16 slides · Aug 6, 2020
Q1 2020 Earnings Presentation14 slides · May 11, 2020
Q3 2019 Earnings Presentation24 slides · Nov 1, 2019
Proxy Contest (September 2019)48 slides · Sep 4, 2019
Q2 2019 Earnings Presentation26 slides · Aug 7, 2019
Investor Day (May 2019)56 slides · May 22, 2019